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Abstract 
Nested reverse-transcriptase polymerase chain reaction (rt-PCR) was performed on 58 leukemia 
patients at BIRDEM Laboratory, as a pioneering work in Bangladesh. Thirty of them were 
examined for the presence of BCR-ABL being clinically and morphologically diagnosed as 
chronic myeloid leukemia (CML) and 28 for PML-RARα fusion transcripts being clinically and 
morphologically diagnosed as acute promyelocytic leukemia (APL/ AML M3). The cases were 
selected for targeted therapy with imatinib mesylate and all-Trans retinoic acid (ATRA) to treat 
CML and APL respectively. Samples were received either before commencement or during 
therapy. In the positive cases, amplified DNA products were visible after gel electrophoresis and 
were reported accordingly. In case of BCR-ABL, positive results were found for five out of six 
(83.33%) untreated cases and 11 out of 24 (45.83%) treated cases. Positive results for PML-
RARα were found for 12 out of 14 (85.70%) untreated cases and 11 out of 16 (68.75%) treated 
cases. A strong positive correlation was found between duration of treatment and negativity of 
PCR results in both the cases. In present times, the detection of minimal residual disease in 
patients undergoing treatment for hematological malignancies has become an important goal, not 
only to monitor the effectiveness of therapy but also to detect an impending relapse. This is the 
first time in Bangladesh that rt-PCR method is being employed to detect or monitor the presence 
of abnormal fusion genes in hematological malignancies.  
 
 
Introduction 
Diagnosis of hematological malignancies is not 
complete unless morphological examination is 
supplemented by further studies like immuno-
phenotyping, karyotyping (conventional cytogene-
tics) and/or molecular studies, etc. Chronic myeloid 
leukemia (CML) and acute promyelocytic leukemia 
(APL) are two prototypes of such diseases. 
Molecular methods such as fluorescence
  in situ 
hybridization (FISH), reverse-transcriptase poly-
merase
  chain reaction (rt-PCR), and real-time 
quantitative rt-PCR have been used to detect the 
chimeric genes in question or their transcripts. 
Detection of specific chromosomal translocations is 
not only a diagnostic tool but is also a strategy to 
assess the response of individual patients to 
therapeutic interventions, and to evaluate treatment 
efficacy by monitoring residual disease. Among the 
various cytogenetic and molecular tests available 
for diagnosis and monitoring of hematological 
malignancies, polymerase chain reaction (PCR) 
based amplification
 assays are the most sensitive of 
all laboratory approaches,
  followed by flow 
cytometry, FISH, and cytogenetics, with associated
 
detection thresholds of about one in one million, 
one in several
  thousand, one in several hundred, 
and one in 20, respectively
1. 
Generally, conventional cytogenetics is the 
recommended test for detecting chromosomal 
aberrations in the form of specific translocations in 
newly diagnosed leukemia patients. However, 
cytogenetic analysis
 requires viable marrow cells or 
more than 10% blasts in the
  peripheral blood to 
reliably culture the cells and visualize
 metaphases. 
Occasionally fibrosis interferes with marrow 
aspiration,
 yielding few analyzable metaphase cells. 
The number of cells
  examined determines the 
sensitivity of karyotyping. A typical
 examination of 
20 cells carries a detection rate of one affected cell 
among 20 cells,
 i.e. 5%. Moreover, as the results   2
may vary largely depending on expertise, manual 
errors are more likely. 
FISH allows detection of
  translocations in either 
metaphase or interphase
  cells. Typically, 200 
interphase or metaphase nuclei are evaluated,
 
yielding a detection rate of about 1 in 200, or 0.5%. 
At present, FISH technology is not yet available in 
Bangladesh. 
Southern blot analysis reliably identifies a certain 
gene rearrangement
  using probes targeting the 
specified breakpoint.
  The Southern blot method 
suffers from high
 cost and slow turnaround time. In 
addition, the assay is not
  sensitive for detecting 
minimal residual disease since tumor
 levels below 
about 5% are not detectable.
  
rt-PCR is the
 most sensitive method described to 
date for detecting chromosomal translocations in 
hematological malignancies.
  Instead of targeting 
chromosomal DNA, the assay targets the
  more 
abundant chimeric RNA transcripts produced from 
the fused
  genes. Chromosomal DNA is an 
impractical target not only because
  it is less 
abundant than RNA but also as the breakpoint
 
regions span such large segments of intronic DNA 
that multiple
 PCR primer sets would be required to 
detect every possible translocation.
  On the other 
hand, the chimeric RNA is remarkably homo-
geneous
 from case to case, thus allowing reliable 
detection of nearly
  all disease-associated 
translocations. 
Amplification assays are capable of detecting one 
affected cell
 among 100,000 or so normal cells, a 
sensitivity unparalleled by any other available 
method
1-3. PCR has thus attracted much attention 
due to the extreme sensitivity and specificity of the 
technique.  
The exceptional sensitivity
 of rt-PCR makes it well 
suited for assessing minimal residual
  disease 
following therapy. rt-PCR can be applied for 
detection of a wide range of fusion transcripts 
found in hematological malignancies. Among them, 
World Health Organization (WHO) has selected 
four fusion transcripts as significant markers for 
monitoring prognosis. They are, BCR-ABL 
[t{9;22}] for CML and PML-RARα[t{15;17}] for 
AML M3 or APL, AML-MTG8 [t{8;21}] for AML 
M2, and CBFβ-MYH11[inv16}] for AML M4Eo
4.  
We have been performing PCR for all four of these 
markers but as targeted therapy is available in the 
first two instances, namely imatinib mesylate 
(STI571) for CML and all-Trans retinoic acid 
(ATRA) for APL, they have more value to the 
physician in terms of therapeutic implications and 
in this setting we are thus publishing the data 
pertaining to those two transcripts only.  
Qualitative rt-PCR, specially nested PCR, has been 
proved to improve our ability to measure residual
 
disease and to forecast risk of relapse in CML and 
APL
5-10. Several clinical trials
  are underway to 
further determine the utility and recommended
 
frequency of laboratory monitoring of CML and 
APL, particularly now
  since targeted therapy is 
available. Interestingly, one
 mechanism of imatinib 
resistance in CML is amplification of the BCR-
ABL
 chimeric gene, leading to over expression of 
the fusion transcript
  rather than the anticipated 
decrease expected with successful
  therapy
11.
  This 
heralds the idea that alternative strategies for 
treatment may be considered once an rt-PCR 
negative patient on imatinib therapy becomes 
positive. 
Real-time quantitative rt-PCR techniques are also 
now available that
 permit quantitative analysis of 
chimeric transcripts. Levels can
 be reported either 
in absolute terms or relative to a housekeeping
 
transcript. Recent studies using this technology to 
detect BCR-ABL or PML-RARα
  transcripts have 
shown good correlation with the results of
 
cytogenetic analysis, FISH, Southern blot analysis, 
and conventional
  nested rt-PCR
12-14. Various 
platforms such as the ABI Prism
  7700 (Applied 
Biosystems, Foster City, CA) or the LightCycler
 
(Roche Diagnostics, Indianapolis IN) were able to 
reproducibly
 detect one positive cell from among 
10,000 to 100,000 normal
 cells
12-20. The drawback 
in our country is that the initial setup including the 
machine is quite expensive. Moreover, standardiza-
tion of results is very important for accurate 
interpretation. On the other hand, the set up for 
qualitative PCR is relatively less costly and easy to 
interpret as it only gives an objective result. 
Therefore, as an initial approach, we have felt that 
it was essential to establish qualitative rt-PCR in 
our country. Our aim was to detect the presence of 
fusion mRNA transcripts in CML and APL, either 
prior to treatment as an aid to confirmation of 
diagnosis, or during the course of treatment, to 
follow-up and detect any residue of leukemia cells 
after hematological remission was achieved. 
 
Materials and Methods 
Patient samples: The entire study was carried out 
in Hematology Section of Laboratory Department, 
Bangladesh Institute of Research and Rehabilitation 
in Diabetes, Endocrine and Metabolic Disorders 
(BIRDEM). Heparinized bone marrow or   3
peripheral blood samples were collected after 
informed consent, from 58 patients provisionally 
diagnosed as leukemia and five non-leukemic 
subjects with apparently normal bone marrow 
findings (control subjects). Median age of the 
patients was 31 years (range 10 to 55 years). A 
summary of the clinical data of these patients is 
presented in Table I. The diagnosis and 
classification of the AML and CML patients were 
based on morphology according to WHO 
classification. Morphology was examined by 
Wright’s staining. The patients included 25 patients 
morphologically diagnosed as CML, 15 as APL, 
and one as acute leukemia by the referring 
clinicians. Samples of 17 patients had been 
collected prior to initiation of therapy, among 
which seven were tested for BCR/ABL and 10 for 
PML/RARα. The rest of the patients had been 
receiving either conventional or targeted therapy 
for their specific malignancies. Samples of five 
patients (patient 6, 8, 18, 23 and 26) were 
investigated twice each at various intervals during 
their treatment tenure.  
Fifteen CML patients received imatinib mesylate, a 
tyrosine kinase inhibitor, at the dose of 400 to 600 
mg daily. The conventional chemotherapy 
regimens included hydroxurea, interferon γ, 
purinethal etc, as decided by the treating physician. 
Out of the APL patients, six patients had received 
all-Trans retinoic acid (ATRA) for more than three 
months, and one patient for 14 days. All of the APL 
patients had received conventional chemotherapy in 
combination with the targeted therapy that 
comprised of various cycles of daunorubicin, 
mitoxantron, purinethal and methotrexate, 
according to the justification of the treating 
physician. A complete hematological remission 
was defined as
  a WBC count of <10 x 10
9/L, a 
platelet count of <450 x
 10
9/L, no immature cells 
(blasts, promyelocytes, myelocytes)
  in the 
peripheral blood, and disappearance of all signs and
 
symptoms related to leukemia (including palpable 
splenomegaly)
  lasting for at least four weeks. A 
complete molecular response
  was defined as 
undetectable levels of BCR-ABL confirmed by 
nested
 PCR. 
Both in case of CML or APL, the patients were 
divided into four groups, Group I, freshly 
diagnosed and sample taken before commencement 
of treatment, Group II, having received less than 
three months of treatment, Group III, as those 
treated for three to six months and Group IV, as 
those treated for more than six months. 
PCR amplification of BCR/ABL or MYL/ RARα 
(PML/ RARα) junctions: Total cellular RNA was 
isolated from appropriate amounts of bone marrow 
or peripheral blood samples that contained from 2 x 
10
6 to 1 x 10
7 leucocytes using a commercial kit 
(QIAamp RNA Blood Mini Kit; QIAGEN GmbH, 
Germany) according to the manufacturer’s 
conditions. Concentration of RNA was measured 
spectrophotometrically and the ratio of optical 
density at 260 and 280 nm checked. A ratio of 1.80 
to 2.00 was accepted as good quality RNA and any 
sample not achieving this target was discarded. In 
vitro reverse transcription of 1 µg or less of total  
Table I. Clinical data of patients selected for rt-PCR 
Sl No. Age  Morphological diagnosis  Target gene  Treatment status 
1 30  APL  PML-RARα  Untreated 
2 13  CML-CP  BCR-ABL  Hydroxurea 
3 30  CML-CP  BCR-ABL  Untreated 
4 24  APL  PML-RARα  Untreated 
5 55  CML-CP  BCR-ABL  Hydroxurea 
6  17  CML-CP  BCR-ABL  Imatinib mesylate for 4 months  
7 55  CML-CP  BCR-ABL  Untreated 
8 43  APL  PML-RARα  ATRA for 1 year 
9  30  CML-CP  BCR-ABL  Hydroxurea for 2 days 
10 47 APL  PML-RARα  ATRA for 7 months 
11 22 CML-CP  BCR-ABL  Untreated 
12  40  CML-CP  BCR-ABL  Imatinib mesylate for 10 days  
13 50 CML-CP  BCR-ABL  Untreated 
14 38 APL  PML-RARα  Untreated   4
15 36 APL  PML-RARα  ATRA for 6 months 
16  33  CML-CP  BCR-ABL  Imatinib mesylate for 1 year 
17 55 CML-CP  BCR-ABL  Untreated 
18 50 APL  PML-RARα  ATRA for 7 days 
19  24  CML-CP  BCR-ABL  Imatinib mesylate for 8 months 
20  35  CML-CP  BCR-ABL  Imatinib mesylate for 7 Months 
21  34  CML-CP  BCR-ABL  Imatinib mesylate for 9 Months 
22  36  CML-CP  BCR-ABL  Imatinib mesylate for 8 Months 
23 24 APL  PML-RARα  Untreated 
24 44 APL  PML-RARα  ATRA for 14 days 
25 18 APL  PML-RARα  Untreated 
26 25 APL  PML-RARα  ATRA for 3 days 
27  60  CML-CP  BCR-ABL  Imatinib mesylate for 3 Months 
28  22  CML-CP  BCR-ABL  Imatinib mesylate for 10 months 
29 28 APL  PML-RARα  Untreated 
30  27  CML-CP  BCR-ABL  IFN+Hydrea+Purinethal, to start Imatinib 
31  7  AL, probably AML/ CML-AP  BCR-ABL  Untreated 
32  38  CML-CP  BCR-ABL  Imatinib for 4 months 
33  50  CML-CP  BCR-ABL  Imatinib for 18 months 
34  27  CML-CP  BCR-ABL  Imatinib for 2 months 
35  29  APL in hematological remission  PML-RARα  Dauno+Mit+ATRA for 1 month 
36  40  APL in hematological remission  PML-RARα  6 cycle of chemo+ ATRA for 7 months 
37  32  CML in hematological remission  BCR-ABL  Imatinib for 4 months 
38  46  CML in hematological remission  BCR-ABL  Imatinib for 15 months 
39 20 APL  PML-RARα  Untreated 
40  23  CML in hematological remission  BCR-ABL  Imatinib for 4 months 
41  24  APL in hematological remission  PML-RARα  ATRA for 3 months 
42  50  APL in hematological remission  PML-RARα  ATRA for 7 months 
43 40 APL    PML-RARα  Untreated 
44 38 CML-CP  BCR-ABL  Untreated 
45 10 APL  PML-RARα  Untreated 
46  25  APL in hematological remission  PML-RARα  ATRA for 4 months 
47 20 APL  PML-RARα  Untreated 
48 28 AML  PML-RARα   Untreated 
49 44 AML  PML-RARα  Treated for 3 years (ATRA+) 
50  7  CML  BCR-ABL  Hydrea for 2 month 
51  30  CML  BCR-ABL  Hydra for 1 Week 
52 30 APL  PML-RARα  Fresh 
53 28 AML  PML-RARα  Untreated 
54 25 AML  PML-RARα  Untreated 
55 17 AML  PML-RARα  Vasonoid for 3 days 
56  50  CML in hematological remission  BCR-ABL  Enliven for 3 months 
57 25 AML  M4  PML-RARα  Untreated 
58 5.5  ?CML  BCR-ABL  Untreated 
   5
 
RNA to cDNA was performed in a 20 µl volume 
for 15 min at 42°C containing Quantiscript reverse 
transcriptase and a mixture of both oligo-dT and 
random hexamers as primers, using a commercial 
kit (Quantitect Reverse Transcription Kit; QIAGEN 
GmbH, Germany) according to the manufacturer’s 
conditions. The reverse transcript-tase included in 
the kit is a mix of Omniscript and Sensiscript 
Reverse Transcriptases, which are recombinant of 
PCR mixture containing 1.5 mmol/L MgCl2, 50 
mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.3, 200 
µmol/L dNTP, 2.5 U of HotStartaq Polymerase and 
400 nmol/L of primers. The temperature conditions 
for each individual primer set are shown in Table 
II. At the end, 1 µl of first PCR product was used 
for a second round of amplification for further 30 
cycles using a nested primer. The sequences of 
forward and reverse oligonucleotide primers used 
for major, minor and micro BCR/ABL, 
PML/RARα  β-actin amplifica-tion were received 
as a kind courtesy from the Department of 
Hematology and Oncology, Hiroshima University, 
Japan and are shown in Table III. Finally, 10 µl of 
PCR product was run on a 2% molecular biology 
grade agarose gel stained with ethidium bromide 
and visualized under a UV transilluminator 
(Optima UVP, Japan) at 365 nm. As positive 
controls, either cell lines or cDNA from samples 
previously found positive for the respective 
translocations, were used. The names of the 
positive control cell lines are provided in Table III. 
Amplification of β-actin mRNA was always 
performed with 1 µl of the same cDNA preparation 
used to identify the respective translocations, and 
thus, presence of good quality cDNA was ensured. 
Table II: Thermal cycling programs for first and nested PCR 
major, minor and micro BCR-ABL  
Initial activation of Taq Polymerase  15 min  95˚C 
3-step cycling     
Denaturation  30 s   94˚C 
Annealing 30  s  55˚C 
Extension 1  min  72˚C 
Number of cycles  30   
Final extension  7 min  72˚C 
 
PML-RARα  
Initial activation of Taq Polymerase  15 min  95˚C 
3-step cycling     
Denaturation  1 min   95˚C 
Annealing 1  min  50˚C 
Extension 1  min  72˚C 
Number of cycles  30   
Final extension  7 min  72˚C 
Interpretation of results: The expected product size 
of major BCR-ABL, was either 446 base pairs (bp) 
when the breakpoint on BCR gene is on exon 14 
and 371 bp when the breakpoint is on exon 13 with 
the primer sets used in our laboratory
21. The expec-   
Table III: Sequences of primers 
  Gene    Name  Primer sequence  Product size  Positive control 
cDNA 
1 Major  BCR-
ABL 
1st BCR1  5'-GCTTCTCCCTGACATCCGTG-3'    KT1  1840 
(e13a2) B3 2415 
(e14a2) 
ABL1 5'-GGCCCATGGTACCAGGAGTG-3' 
2nd BCR2  5'-GGAGCTGCAGATGCTGACCAAC-3' 446  bp  (e14a2) 
371 bp (e13a2)  ABL2 5'-GTTTCTCCAGACTGTTGACTG-3' 
2 minor  BCR-
ABL 
1st BCR3  5'-CGCATGTTCCGGGACAAAAGC-3'    Hirata  2834 
ABL1  
2nd BCR4  5'-CGCTCTCCCTCGCAGAACTC-3'  472  bp 
ABL2  
3 micro  BCR-ABL 1st  BCRc30+  5’-AGAGGTCCAAGGTGCCCTAC-3’    × 
ABL1  
2nd BCRc31+  5’-CGGACATCCAGGCACTGAAG-3’  329  bp 
ABL2  
4  PML-RARα  1st PML  M4  5'-AGCTGCTGGAGGCTGTGGA 
CGCGCGGTACC-3' 
 Kimura  1224 
RARa R5  5'-CCACTAGTGGTAGCCTGAGGACT-3' 
2nd PML  M4   400-700  bp   6
RARa R8  5'-CAGAACTGCTGCTCTG 
GGTCTCAAT-3' 
5  PML-RARα 
(alternative) 
1st PML  M2  5'-AGTGTACGCCTTCTCCATCA-3'   
RARa R5  5'-CCACTAGTGGTAGCCTGAGGACT-3' 
2nd PML  M2   200-400  bp. 
RARa R8  5'-CAGAACTGCTGCTCTGG 
GTCTCAAT-3' 
 
ted product sizes for minor and micro BCR/ABL 
were 472 bp and 329 bp respectively. In case of 
PML/RARα, due to alternative splicing of the 
breakpoint cluster regions (BCR) on myl locus of 
chromosome 15, PCR products of various sizes 
ranging from 400 to 700 bp were found with M4 
primer which is found to be a “universal primer” 
for all the three forms of translocations seen in APL 
(short isoform: intron 3-bcr 3; long variant isoform: 
exon 6-BCR 2; and long isoform: intron 6-BCR 1)
 
16-18. A single product of either 326 bp or 290 bp 
was observed with m2 primer, that corresponded to 
the translocation breakpoints intron 6-BCR 1 and 
exon 6-BCR 2 respectively
8, 22, 23. No band was 
seen with m2 primer when the breakpoint lay in the 
intron 3-BCR 3 region of myl locus. Accordingly, 
the results of nested PCR for BCR/ABL were 
interpreted as major, minor or micro isoform and 
for PML/RAR alpha as long (l), long variant (v) 
isoform or short (s) isoform. 
 
Results 
RNA isolated from bone marrow or peripheral 
blood samples of 26 patients were examined for the 
presence of the BCR-ABL and 24 for PML-RARα 
fusion transcript.  
PML-RARα:  The patients examined for PML-
RARα were diagnosed either as acute myeloid 
leukemia or APL by morphology. 
Group I: 14 patients belonged to this group, who 
had been provisionally diagnosed as APL and the 
samples collected prior to initiation of therapy. All 
of the 10 samples came out to be positive (10/10) 
for PML-RARα by nested PCR. Therefore, there 
was a strong concurrence between morphological 
impression and the results of PCR in these cases. 
Group II:  One patient (patient 35) had been 
receiving treatment comprising of conventional 
chemotherapy along with ATRA, for less than three 
months. The sample showed presence of PML-
RRAα fusion transcripts. 
Group III: Three patients (patient 15, 41 and 46) 
fell in this group. The results were positive in all 
(3/3) the cases. Two out of three patients (patient 
41 and 46) had been examined prior to treatment 
(patient 23 and 26) and had been found positive for 
PML-RARα in that instance also.  
Group IV: Five patients were included in this 
group. All of them had received ATRA alone or in 
combination with other conventional chemothera-
peutic drugs. Two (2/5) were found negative and 
three (3/5) positive by nested PCR. Between the 
two negative cases, one (patient 42) had been 
examined previously (patient 18) at the time of 
commencement of therapy and had been positive at 
that time (Figure 1). Among the three positive 
cases, one (patient 49) had been examined prior to 
therapy (patient 8) and had been positive at that 
time too. 
BCR-ABL:  Among the cases examined for BCR-
ABL, 25 had provisionally been diagnosed as 
suffering from CML, and one as acute leukemia. 
Group I:  There were 10 patients in this group, 
seven morphologically compatible with CML and 
one with acute leukemia with more than 50% of 
blasts. All the seven CML cases showed presence 
(7/7) of major BCR-ABL transcripts. The one acute 
leukemia patient showed absence (0/1) of any of 
the three BCR-ABL transcripts (major, minor or 
micro BCR-ABL). Therefore, the results of 
molecular analysis correlated strongly with the 
morphological appearance. 
Group II: Two patients (patient 2 and 34) had 
received treatment for less than three months. 
Between them, one (patient 2) was receiving 
hydroxurea only and had not achieved 
hematological remission. The other one (patient 34) 
was receiving imatinib mesylate and was in 
hematological remission. Both the patients (2/2) 
were found positive for BCR-ABL by nested PCR. 
 
 
   7
 
 
 
 
 
Figure 1: PCR amplification of the myl/RARα junction of an APL patient prior to treatment (patient 18) and the same patient after six 
months of therapy (patient 42) with All-trans Retinoic Acid (ATRA). Primers M4 (A) or M2 (B) and R5 were used as a first cycle of PCR; 
then a second round of amplification was performed by using R8 as nested primer. The first sample (patient 18) showed a BCR 1 type of 
PML/RAR alpha fusion transcript with a band size of 326 bp by the M2/R8 set of primers (B), which disappeared after treatment for six 
months. 
 
 
 
 
Figure 2:  Nested rt-PCR for BCR-ABL. Patient 12 shows the e14a2 isoform of major BCR-ABL (product size 446 bp) and patient 13 
shows the e13a2 isoform (371 bp) while cDNA isolated from a normal control person shows no amplification of the BCR-ABL fusion 
transcript. The bands below are rt-PCR products for the β-actin mRNA. 
 
Group III: There were nine patients in this group. 
Karyotyping had been attempted in four of these 
cases, with a negative result in one case and sample 
turned out to be inadequate for analysis in three 
cases. Four of the patients had not achieved 
hematological remission and five were in complete 
hematological remission (CHR). Accordingly the 
patients were subdivided into two groups, Group III 
A and Group IIIB respectively. In Group IIIA, two 
patients were receiving (patient 21 and 22) imatinib 
mesylate while the other two (patient 5 and 30) 
were on conventional chemotherapy regimen. All 
four of the patients in Group IIIA were positive 
(4/4) for major BCR-ABL. Among them, one was 
found to be negative for Philadelphia chromosome 
by conventional karyotyping. In Group IIIB, all of 
the patients were receiving imatinib mesylate. Two 
of the patients (patient 6 and 32) were positive (2/5) 
for major BCR-ABL and the rest of the three (3/5) 
were negative. Therefore the molecular responses 
according to our tests, correlated well with the 
hematological profiles of the patients.  
Group IV: Six patients belonged to this group. Five 
of them turned out to be negative (5/6) for any of 
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the three isoforms of BCR-ABL fusion transcripts. 
One (patient 38) was positive for minor BCR-ABL. 
In this case also, there was a strong correlation 
between the hematological response and results of 
our tests. 
Overall, among the cases positive for major BCR-
ABL, both the two isoforms (e13a2 and e14a2) 
were found among our cases (Figure 2). Three 
cases possess the e13a2 for while the rest had the 
e14a2 isoform. 
 
Discussion 
Recent advances in molecular genetics impact the 
health care
  and outcome of patients with 
hematological malignancies.
 BCR-ABL, a common 
molecular defect in CML, and PML-RARα in APL, 
are valuable
  tumor markers whose detection 
influences prognosis and clinical
  management 
decisions. Analysis of tumor-specific translocations 
is a promising means
  for evaluating minimal 
residual disease in those patients whose
  tumor 
harbors a translocation for which a reliable 
laboratory
  assay is available. Accordingly, we 
performed rt-PCR in patients morphologically 
suspected to be suffering from leukemia, either for 
confirmation of diagnosis in untreated cases or to 
detect residual disease in treated ones. We took a 
nested PCR approach and restricted ourselves to 
qualitative analysis only, as an initial step.  
PML-RARα: According to duration of treatment of 
ATRA, we classified the treated cases into four 
groups. The first group was newly diagnosed and 
had not received any treatment at all. There were 
14 patients morphologically suspected to be 
suffering from APL, who had not received 
treatment. Twelve of them were positive for PML-
RARα by our method while two were negative. The 
two negative cases may be harboring a 
translocation different from PML-RARα, like 
promyelocytic leukemia zinc finger PLZF-RARα {t 
(11; 17)(q23; q21)} that is occasionally found in 
APL
24, 25.  This could not be confirmed, as we did 
not have any means of identifying the latter 
translocation. On the other hand, two other cases 
that were suspected to have morphology of AML 
other than M3 were also tested for the presence of 
PML-RARα, and one found to be positive and the 
other negative. The positive one contained 
monocytoid blasts in bone marrow and PBF, which 
may be a variant form of APL with hypogranular 
promyelocytes. The other one had been 
provisionally diagnosed as AML M4.  
The second had received treatment for less than 35 
days. According to the observation of National 
Comprehensive Cancer Network (NCCN), 
molecular remission is not achieved before 35 
days
26. There were four cases in this group. All 
were found PCR-positive by our method, which is 
comparable to the observation of other researchers 
including NCCN. 
The third group had received treatment for more 
than 35 days but had not received more than 3 
cycles of consolidation chemotherapy. Two cases 
fell in this group, both of which were found 
positive. Though a molecular remission may be 
achieved within this time, it has been observed in 
many clinical trials that it may not always be 
achieved before 2-3 courses of consolidation
26. 
Therefore it may be too early to classify these as 
induction failure; rather they may be kept under 
follow-up for molecular residual disease. 
The fourth group had received treatment for more 
than six months, including more than 3 cycles of 
consolidation and all were in hematological 
remission. Four (4/6) cases were found PCR 
positive while two (2/6) were found PCR negative. 
Further follow-up by PCR as well as clinical 
observation for relapse is required to correlate the 
results with the prognosis of the patients. 
Biondi et al
8 have shown that PCR amplification of 
the PML/RARα gene is an easy and rapid method 
for detection and monitoring of the malignant clone 
in APL. Moreover, it has been seen that 
achievement of negative rt -PCR in remission is 
associated with favorable RFS and OS. Continuous 
negative rt-PCR results are associated with long-
term relapse-free survival and may be considered as 
potentially curative
9. Other researchers have 
supported this data
10, 27-30.
  
BCR-ABL: Molecular monitoring provides valuable 
information
 for the follow-up of patients with CML 
in chronic phase treated
 with imatinib. Achieving a 
major molecular response correlated
  with an 
improved probability of a durable cytogenetic 
remission,
 particularly when achieved early during 
the course of therapy.
  Most major molecular 
remissions have been durable, and increases
  in 
BCR-ABL transcripts have not translated in loss of 
cytogenetic
  remission for most patients with 
molecular response. Thus, a
 major goal of therapy 
with imatinib should be to achieve an
 early major 
molecular response.
  
We divided the patients examined for BCR-ABL 
into four groups according to their treatment status. 
The first group consisted of six patients with 
morphology compatible with CML-CP, who had 
not received treatment. Five (5/6) were PCR 
positive for major BCR-ABL and one was   9
negative. The negative one may be atypical CML 
(aCML), which has been included in the new WHO 
classification of leukemia
4 or may not be CML at 
all.  
Alongside, we had analyzed two other untreated 
cases, which were clinically suspected by various 
clinicians to be suffering from CML, but the 
morphology at the time of collection of the sample 
did not resemble the disease. Both (2/2) were 
negative for PCR. Therefore, the test may be 
helpful in excluding a diagnosis like malignancy 
when a leucocytosis presented by a patient might 
be reactive only. This will help avoid exposure to 
toxic drugs as well as undue expenses and worry of 
the patents and their relatives. 
The second group comprised of six patients who 
had received treatment, either imatinib mesylate or 
hydroxurea, but for duration of less than three 
months. Four (4/6) were PCR positive while two 
(2/6) turned out to be negative. As the presence of 
Philadelphia chromosome had not been confirmed 
in any of the cases before commencement of 
therapy, the possibility remains that the negative 
two did not bear the aberrant chromosome at all. 
On the other hand, it can be said that it is too early 
to look for molecular remission before three 
months as observed by the positive cases
31.  
The third group had 10 patients who had received 
either imatinib mesylate or conventional 
chemotherapy, for three to six months. Four (4/10) 
had not achieved hematological remission while six 
(6/10) had done so. All of the first four were PCR 
positive while among the other six, three (3/6) were 
positive and the rest of the three (3/6) were 
negative. The question remains whether six months 
is also too early to declare them as treatment 
failure. According
 to the recent practice guidelines 
of NCCN, after hematological remission
  is 
achieved during treatment with imatinib mesylate, 
cytogenetics
 and rt-PCR should be done every three 
months for the first 2
 years and every six months 
for the next three years.
 32 A search for kinase 
domain mutations is recommended if complete 
cytogenetic remission is not achieved after six 
months
32.
 
The fourth group had six patients who had received 
imatinib Mesylate for more than six months and all 
were in hematological remission. All the six (6/6) 
were PCR negative. Therefore, it may be said that 
all were in molecular remission and the therapy had 
been effective. 
Many investigators have reported, with varying 
results, on the detection of minimal residual disease 
by nested PCR in patients with CML. Roth et al
6 
analyzed 64 CML patients after allogeneic SCT and 
detected BCR-ABL transcripts at one time point in 
37 of the patients. Of those 37, 13 eventually had a 
disease relapse, with a median time to relapse of 5 
months. No relapses were observed in patients with 
negative PCR results. Roth et al
6 thus concluded 
that nested PCR could define subgroups of patients 
in apparent clinical remission but with an increased 
risk of disease recurrence. In contrast, Miyamura et 
al,
7 also using nested PCR, detected no association 
between PCR positivity and subsequent relapse in 
their series of 64 patients with CML in remission 
after allogeneic SCT. In five cases, the persistence 
of detectable BCR-ABL transcript for up to 2 years 
post-remission did not result in disease recurrence. 
Hughes et al, 
33 on the basis of nested PCR results 
in 37 CML patients in remission after allogeneic 
SCT, concluded that PCR positivity within 6 
months after transplantation did not predict a worse 
outcome, whereas PCR positivity later than 6 
months after transplantation did. 
The PCR technique, although considered a valid 
clinical testing procedure, should be used 
cautiously as a laboratory test until sufficient data 
are available to show that it meets acceptable 
criteria of sensitivity, specificity, and positive and 
negative predictive values. How new PCR 
technologies such as ‘‘realtime’’ PCR quantifica-
tion will solve these concerns and become a 
reliable tool for the clinician merits further 
investigation. On the horizon are
 gene expression 
profiles that will likely provide additional
 
information beyond what is obtainable with current 
clinical
 and laboratory approaches. 
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